Benefits
Endothelial function support
Standardized amla extract supports endothelial function as measured by digital volume pulse reflection index in adults with type 2 diabetes and metabolic syndrome, with the higher tested dose performing comparably to atorvastatin 10 mg in head-to-head clinical comparison.
Oxidative stress reduction
Daily Amlamax-class amla extract lowers malondialdehyde and elevates nitric oxide bioavailability in cardiometabolic populations, reflecting reduced systemic oxidative damage and better redox balance over a 12-week course.
Healthy lipid profile
Standardized amla extract reduces LDL cholesterol and triglycerides and improves the total-cholesterol-to-HDL ratio in overweight adults and people with metabolic syndrome, helping maintain a cardiovascular-friendly lipid profile.
Inflammation balance
Amlamax-class amla extract significantly lowers hsCRP in adults with elevated cardiometabolic risk, helping support a healthy inflammatory state alongside diet and physical activity.
Mechanism of action
Hydrolyzable tannin antioxidant chemistry
Emblicanin A and B, punigluconin, and gallic acid quench reactive oxygen species, chelate transition metals that catalyze radical reactions, and release sustained vitamin-C-like reducing activity over several hours of gut hydrolysis.
NF-κB downregulation and Nrf2 activation
Amla polyphenols downregulate NF-κB-driven cytokine transcription and concurrently activate the Nrf2 pathway, increasing endogenous antioxidant enzyme expression — a dual anti-inflammatory and antioxidant mechanism.
Endothelial NO preservation
By reducing local superoxide flux in vascular tissue, amla polyphenols preserve nitric oxide bioavailability and support smooth-muscle relaxation, improving reflection index and flow-mediated vascular endpoints.
Clinical trials
Randomized, double-blind, controlled study in 80 adults with type 2 diabetes comparing standardized P. emblica extract (250 mg twice daily, 500 mg twice daily), atorvastatin 10 mg, and placebo for 12 weeks. Endpoints: endothelial function (reflection index), malondialdehyde, glutathione, hsCRP, lipid profile, HbA1c.
80 adults with type 2 diabetes. 12 weeks.
All active groups significantly improved endothelial function versus placebo. The 500 mg twice-daily amla arm produced reductions in malondialdehyde (~28%) and hsCRP (~63%) comparable to atorvastatin 10 mg, with improvements in lipid profile and HbA1c. Well-tolerated across all arms.
Randomized, double-blind, placebo-controlled study of standardized aqueous P. emblica fruit extract (250 mg or 500 mg twice daily) for 12 weeks in 59 adults with metabolic syndrome. Outcomes: endothelial function, oxidative stress, inflammation (hsCRP), and lipid profile.
59 adults with metabolic syndrome. 12-week intervention.
The 500 mg twice-daily dose produced the largest improvements: nitric oxide increased ~51%, malondialdehyde decreased ~31%, hsCRP decreased ~54%, LDL-C decreased ~22%, and triglycerides decreased ~19% versus placebo. Authors concluded the extract may be useful as an adjunct to conventional cardiometabolic care.
12-week supplementation trial with standardized P. emblica extract (500 mg twice daily) in overweight and class-1 obese US adults. Measured calculated LDL cholesterol, total cholesterol/HDL, hsCRP, and platelet aggregation.
Overweight and class-1 obese adults (BMI 25–35).
Significant reductions in calculated LDL cholesterol, total cholesterol/HDL ratio, and hsCRP. ADP- and collagen-induced platelet aggregation also significantly decreased after 12 weeks of supplementation.